Sandoz acquires CIMERLI®, a biosimilar from Coherus, to strengthen its ophthalmic platform in the US.
Sandoz, a global leader in generic and biosimilar medicines, has completed the acquisition of CIMERLI® (ranibizumab-eqrn), a biosimilar from Coherus BioSciences. The acquisition bolsters Sandoz's ophthalmic platform in the US and strengthens its biosimilar and ophthalmology leadership. CIMERLI is interchangeable with LUCENTIS® for all approved indications, ensuring a seamless experience for providers and patients.
March 04, 2024
10 Articles